Management of preterm labor: atosiban or nifedipine?
International Journal of Women's Health, 2010 Roel de Heus, Eduard J H Mulder, Gerard H A VisserDepartment of Woman and Baby, University Medical Centre Utrecht, The NetherlandsAbstract: Preterm birth is strongly associated with neonatal death and long-term neurological morbidity.
Roel de Heus +2 more
doaj +6 more sources
Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up [PDF]
BMJ OpenIntroduction Currently, the majority of women worldwide with threatened preterm birth are treated with tocolytics. Although tocolytics can effectively delay birth for 48 hours, no tocolytic drug has convincingly been shown to improve neonatal outcomes ...
Martijn A Oudijk +7 more
doaj +2 more sources
Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy
Clinical and Experimental Obstetrics & Gynecology, 2021 It is known that atosiban has fewer side effects than conventional tocolytics. In clinical practice, however, hyperglycemia can be commonly observed in mothers who have been administered atosiban.
Hyun Jin Ko +2 more
doaj +1 more source
Efficacy of atosiban for repeated implantation failure in frozen embryo transfer cycles
Scientific Reports, 2023 Atosiban was commonly added to improve pregnancy outcomes of patients with repeated embryo implantation failure (RIF). In this study, we aimed to investigate the effect of atosiban before transferring the frozen-thawed embryo to RIF patients.
Xiufang Li +6 more
doaj +1 more source
Scientific Reports, 2023 To assess the effect of atosiban in pregnancy outcomes of the fresh embryo transfer (ET), the retrospective cohort study was conducted. Six hundred and eighty-nine cases (using atosiban) and 1377 age and ET cycle-matched controls were collected from the ...
Jie Li, Sien Mo, Zhong Lin, Qiuling Shi
doaj +1 more source
School Performance After Maintenance Tocolysis With Nifedipine for Threatened Preterm Birth: 12-Year Follow-Up of the APOSTEL 2 Trial. [PDF]
BJOGABSTRACT Objective To evaluate school performance at 12 years of age in children prenatally exposed to maintenance tocolysis with nifedipine versus placebo. Design 12‐year follow‐up of the multicentre APOSTEL 2 trial, in which participants with threatened preterm birth between 26+0 and 32+2 weeks of gestation, who remained pregnant after initial 48‐h ...
van der Windt LI +8 more
europepmc +2 more sources
BMC Pregnancy and Childbirth, 2022 Background Worldwide, nifedipine and atosiban are the two most commonly used tocolytic agents for the treatment of threatened preterm birth. The aim of this study was to evaluate the effectiveness of nifedipine and atosiban in an individual participant ...
Tijn M. S. van Winden +9 more
doaj +1 more source
Correction to 'Integrating Bulk RNA and Single-Cell RNA Sequencing Identifies and Validates Lactylation-Related Signatures for Intervertebral Disc Degeneration'. [PDF]
J Cell Mol MedJournal of Cellular and Molecular Medicine, Volume 30, Issue 6, March 2026.
europepmc +2 more sources
Efficacy of atosiban for repeated embryo implantation failure: A systematic review and meta-analysis
Frontiers in Endocrinology, 2023 BackgroundRepeated embryo implantation failure (RIF) posed a significant challenge in assisted reproduction. Evidence of its therapeutic effectiveness including atosiban used around embryo transfer to improve pregnancy outcomes in RIF patients undergoing
Ruxin Wang +6 more
doaj +1 more source
Journal of Human Reproductive Sciences, 2018 Background: Recent developments in assisted reproductive technology focus on potential advances to improve its success rate. Atosiban, a combined oxytocin/vasopressin V1a receptor antagonist, is a novel class of drug involved in basic priming of the ...
Vineet Mishra +5 more
doaj +1 more source